ClinicalTrials.Veeva

Menu

L Reuteri for the Prevention of Nosocomial Diarrhea (PND)

M

Medical University of Warsaw

Status and phase

Completed
Phase 3

Conditions

Nosocomial Infection
Diarrhea
Gastroenteritis

Treatments

Dietary Supplement: Lactobacillus reuteri (DSM 17938)

Study type

Interventional

Funder types

Other

Identifiers

NCT01046656
152/2009

Details and patient eligibility

About

Nosocomial diarrhea is any diarrhea that a patient contracts in a health-care institution. In children, it is commonly caused by enteric pathogens, especially rotavirus. The reported incidence ranges from 4.5 to 22.6 episodes per 100 admissions. Nosocomial diarrhea may prolong the hospital stay and increase medical costs. One of the potential strategies for the prevention of nosocomial infections is the use of probiotics. The number of studies have shown the efficacy of Lactobacillus reuteri (DSM 17938) in the treatment of acute diarrhea. However, there are no data on the efficacy of L. reuteri in the prevention of nosocomial diarrhea. The investigators, therefore, plan to perform the study with the aim of evaluating the role of Lactobacillus reuteri DSM 17938 administration in the prevention of nosocomial gastroenteritis in a pediatric hospital setting.

Full description

Infants will be randomly assigned at admission to receive L. reuteri in dose of 10(8) CFU in 5 drops of oil suspension or a comparable placebo once daily for the entire duration of their hospital stay.

Patients will be evaluated daily for stool number and consistency. In case of loose or watery stools occurring within 3 days after discharge, patients will be advised to contact hospital physicians. Stool samples obtained weekly and during an episode of diarrhea, will be analyzed for bacteria with standard stool cultures and rotavirus and adenovirus antigen.

Enrollment

106 estimated patients

Sex

All

Ages

1 to 48 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age 1-48 mo
  • cause of hospitalization must be other than acute gastroenteritis or diarrhea

Exclusion criteria

  • acute gastroenteritis within 3 days before admission
  • other symptoms which suggest gastroenteritis
  • usage of probiotics and/or prebiotics within 7 days before admission
  • visible blood in the stool
  • patient in bad condition
  • lack of approval from patients parents
  • breastfeeding
  • no compliance

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems